Stay updated with breaking news from Roche Vabysmo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Regeneron were down over 2% in premarket trading. Eylea, jointly developed with Bayer AG, has driven Regeneron's earnings for years, but sales have now come under pressure, partly from Roche's Vabysmo that secured U.S. approval in 2022. Regeneron has set its hopes on a higher-dose version of Eylea.
Regeneron Pharmaceuticals on Thursday beat Wall Street estimates for third-quarter profit, driven by strong demand for its eczema treatment Dupixent. On an adjusted basis, the company...
The company's growth fuel isn't running out yet.
Read the latest Regeneron headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Regeneron...
The biotech's focus on innovation could be a boon for shareholders.